Bio-Rad Laboratories (BIO) Cash from Financing Activities (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Cash from Financing Activities data on file, last reported at -$44.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$44.0 million, up 54.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$229.5 million (up 27.49% YoY), and the FY2025 annual result was -$283.2 million, down 29.43% from the prior year.
• Cash from Financing Activities fell to -$44.0 million in Q1 2026 per BIO's latest filing, from $3.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.2 billion in Q1 2022 and troughed at -$202.7 million in Q2 2023.
• A 5-year average of $125000.0 and a median of -$69.5 million in 2022 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 2613.98% in 2022 and fell as far as 4334.76% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at -$86.6 million in 2022, then sank by 131.62% to -$200.6 million in 2023, then soared by 86.94% to -$26.2 million in 2024, then soared by 112.6% to $3.3 million in 2025, then tumbled by 1433.33% to -$44.0 million in 2026.
• Business Quant data shows BIO's Cash from Financing Activities at -$44.0 million in Q1 2026, $3.3 million in Q4 2025, and -$52.5 million in Q3 2025.